Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D07UBR
|
|||
| Former ID |
DNC006886
|
|||
| Drug Name |
Cis-N,5-dibenzyl-6-oxomorpholine-3-carboxamide
|
|||
| Synonyms |
CHEMBL215688; cis-N,5-dibenzyl-6-oxomorpholine-3-carboxamide
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C19H20N2O3
|
|||
| Canonical SMILES |
C1C(NC(C(=O)O1)CC2=CC=CC=C2)C(=O)NCC3=CC=CC=C3
|
|||
| InChI |
1S/C19H20N2O3/c22-18(20-12-15-9-5-2-6-10-15)17-13-24-19(23)16(21-17)11-14-7-3-1-4-8-14/h1-10,16-17,21H,11-13H2,(H,20,22)/t16-,17-/m0/s1
|
|||
| InChIKey |
ORMAGLLOPOBCBO-IRXDYDNUSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Voltage-gated calcium channel alpha Cav3.1 (CACNA1G) | Target Info | Inhibitor | [1] |
| Voltage-gated calcium channel alpha Cav3.2 (CACNA1H) | Target Info | Inhibitor | [1] | |
| KEGG Pathway | MAPK signaling pathway | |||
| Calcium signaling pathway | ||||
| Circadian entrainment | ||||
| Type II diabetes mellitus | ||||
| Panther Pathway | Endogenous cannabinoid signaling | |||
| GABA-B receptor II signaling | ||||
| Nicotine pharmacodynamics pathway | ||||
| Pathwhiz Pathway | Muscle/Heart Contraction | |||
| Pathway Interaction Database | Regulation of nuclear beta catenin signaling and target gene transcription | |||
| Reactome | NCAM1 interactions | |||
| WikiPathways | Corticotropin-releasing hormone | |||
| NCAM signaling for neurite out-growth | ||||
| Nicotine Activity on Chromaffin Cells | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Morpholin-2-one derivatives as novel selective T-type Ca2+ channel blockers. Bioorg Med Chem Lett. 2006 Oct 1;16(19):5244-8. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.